Literature DB >> 17309545

Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective.

E S A van den Akker1, D Oepkes, E Lopriore, A Brand, H H H Kanhai.   

Abstract

OBJECTIVE: To describe the outcome of pregnancies with fetal and neonatal alloimmune thrombocytopenia (FNAIT) in relation to the invasiveness of the management protocol.
DESIGN: Retrospective analysis of prospectively collected data from a national cohort.
SETTING: Leiden University Medical Centre, the national centre for management of severe red cell and platelet alloimmunisation in pregnancy. POPULATION: Ninety-eight pregnancies in 85 women with FNAIT having a previous child with thrombocytopenia with (n= 16) or without (n= 82) an intracranial haemorrhage (ICH).
METHODS: Our management protocol evolved over time from (1) serial fetal blood samplings (FBS) and platelet transfusion (n= 13) via (2) combined FBS with maternal intravenous immunoglobulins (n= 33) to (3) completely noninvasive treatment with immunoglobulins only (n= 52 pregnancies, resulting in 53 neonates). Perinatal outcome was assessed according to the three types of management. MAIN OUTCOME MEASURES: Occurrence of ICH, perinatal survival, gestational age at birth and complications of FBS.
RESULTS: All but one of 98 pregnancies ended in a live birth; none of the neonates had an ICH. The median gestational age at birth was 37 weeks (range 32-40). In groups 1 and 2, three emergency caesarean sections were performed after complicated FBS, resulting in two healthy babies and one neonatal death.
CONCLUSION: Noninvasive antenatal management of pregnancies complicated by FNAIT appears to be both effective and safe.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309545     DOI: 10.1111/j.1471-0528.2007.01244.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  9 in total

1.  Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion.

Authors:  Günther Giers; Folker Wenzel; Markus Stockschläder; Regina Riethmacher; Horst Lorenz; Boris Tutschek
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.

Authors:  Cheryl A Vinograd; James B Bussel
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

3.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

4.  Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort.

Authors:  Marije M Kamphuis; Heidi Tiller; E S van den Akker; Magnus Westgren; Eleonor Tiblad; Dick Oepkes
Journal:  Fetal Diagn Ther       Date:  2016-10-12       Impact factor: 2.587

5.  Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin.

Authors:  N Margreth Van Der Lugt; Marije M Kamphuis; Noortje P M Paridaans; Anouk Figee; Dick Oepkes; Frans J Walther; Enrico Lopriore
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

6.  Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven.

Authors:  S A Pasman; L Claes; L Lewi; D Van Schoubroeck; A Debeer; M Emonds; E Geuten; L De Catte; R Devlieger
Journal:  Facts Views Vis Obgyn       Date:  2015

7.  Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.

Authors:  Sandra Wienzek-Lischka; Angelika Sawazki; Harald Ehrhardt; Ulrich J Sachs; Roland Axt-Fliedner; Gregor Bein
Journal:  Arch Gynecol Obstet       Date:  2020-06-04       Impact factor: 2.344

8.  Successful management of neonatal alloimmune thrombocytopenia in the second pregnancy: a case report.

Authors:  Fabiana Mendes Conti; Sergio Hibner; Thiago Henrique Costa; Marcia Regina Dezan; Maria Giselda Aravechia; Ricardo Antonio D Almeida Pereira; Andrea Tiemi Kondo; Élbio Antônio D'Amico; Mariza Mota; José Mauro Kutner
Journal:  Einstein (Sao Paulo)       Date:  2014 Jan-Mar

Review 9.  Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention.

Authors:  Ewa Brojer; Anne Husebekk; Marzena Dębska; Małgorzata Uhrynowska; Katarzyna Guz; Agnieszka Orzińska; Romuald Dębski; Krystyna Maślanka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-11-12       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.